Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Ellen Cusano, Haowei Linda Sun, M Dawn Goodyear, Man-Chiu Poon, Douglas Seal, R Scott McClure, Natalia Rydz

Blood (2022) 140 (Supplement 1): 2759–2761.

https://doi.org/10.1182/blood-2022-168133

Published: 2022

Journal Articles

Modified Actriib-Fc Fusion Protein (ACE-536) Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease

Rajasekhar NVS Suragani, PhD, Robert Li, Sharon M Cawley, R. Scott Pearsall, Ravindra Kumar

Blood (2014) 124 (21): 4055.

https://doi.org/10.1182/blood.V124.21.4055.4055

Published: 2014

Journal Articles

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Rajasekhar N. V. S. Suragani, Sharon M. Cawley, Robert Li, Samantha Wallner, Mark J. Alexander, Aaron W. Mulivor, Sara Gardenghi, Stefano Rivella, Asya V. Grinberg, R. Scott Pearsall, Ravindra Kumar

Blood (2014) 123 (25): 3864–3872.

https://doi.org/10.1182/blood-2013-06-511238

Published: 2014

Includes: Supplemental data

Journal Articles

Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia In a Murine Model Of Myelodysplastic Syndrome and Improves Overall Survival

Rajasekhar NVS Suragani, PhD, Robert Li, Sharon Cawley, R. Scott Pearsall, Ph.D., Ravi Kumar, Ph.D.

Blood (2013) 122 (21): 749.

https://doi.org/10.1182/blood.V122.21.749.749

Published: 2013

Journal Articles

ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia

Rajasekhar NVS Suragani, Robert Li, Sharon Cawley, Stefano Rivella, PhD, R. Scott Pearsall, Ravindra Kumar

Blood (2012) 120 (21): 248.

https://doi.org/10.1182/blood.V120.21.248.248

Published: 2012

Journal Articles

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in a Murine Model of Myelodysplastic Syndromes

Rajasekhar NVS Suragani, Robert Li, Dianne Sako, Asya Grinberg, R. Scott Pearsall, Ravindra Kumar

Blood (2012) 120 (21): 3796.

https://doi.org/10.1182/blood.V120.21.3796.3796

Published: 2012

Journal Articles

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in Myelodysplastic Syndromes

Rajasekhar NVS Suragani, Aaron Mulivor, R. Scott Pearsall, Ravindra Kumar

Blood (2011) 118 (21): 610.

https://doi.org/10.1182/blood.V118.21.610.610

Published: 2011

Journal Articles

Linking air pollution exposure with thrombosis

Gökhan M. Mutlu, Paul J. Bryce, G. R. Scott Budinger

Blood (2011) 118 (9): 2636–2637.

https://doi.org/10.1182/blood-2011-07-367144

Published: 2011

Journal Articles

RAP-536 Accelerates Recovery From Chemotherapy-Induced Anemia (CIA) without Promoting Tumor Growth In Murine Models of Cancer and CIA

Samuel M. Cadena, Rajasekhar NVS Suragani, Dianne Mitchell, Jeff Ucran, Katia Liharska, Dianne Sako, Travis Monnell, Kathryn Underwood, Ravindra Kumar, R. Scott Pearsall

Blood (2010) 116 (21): 4230.

https://doi.org/10.1182/blood.V116.21.4230.4230

Published: 2010

Journal Articles

ACE-536, a Modified Type II Activin Receptor Increases Red Blood Cells In Vivo by Promoting Maturation of Late Stage Erythroblasts

Rajasekhar NVS Suragani, Samuel M. Cadena, Dianne Mitchell, Dianne Sako, Monique Davies, Kathleen Tomkinson, Mathew Devine, Jeff Ucran, Asya Grinberg, Kathryn Underwood, R. Scott Pearsall, Jasbir Seehra, Ravindra Kumar

Blood (2010) 116 (21): 4236.

https://doi.org/10.1182/blood.V116.21.4236.4236

Published: 2010

Journal Articles

RAP-536, A Soluble Activin Receptor Type IIb Murine IgG-Fc Fusion Protein, Prevents Myelodysplastic Syndrome Related Anemia

Aaron Mulivor, Samuel M. Cadena, Rajasekhar NVS Suragani, Ravindra Kumar, Kathryn Underwood, Jas Seehra, R. Scott Pearsall

Blood (2010) 116 (21): 978.

https://doi.org/10.1182/blood.V116.21.978.978

Published: 2010

Journal Articles

RAP-011, a Soluble Activin Receptor Type IIa Murine IgG-Fc Fusion Protein, Prevents Chemotherapy Induced Anemia.

Aaron W Mulivor, Ph.D., Denise Barbosa, Ravi Kumar, Ph.D., Matthew Leigh Sherman, MD, Jas Seehra, R. Scott Pearsall, Ph.D.

Blood (2009) 114 (22): 161.

https://doi.org/10.1182/blood.V114.22.161.161

Published: 2009

Journal Articles

Hematologic and Hospitalization Outcomes in Patients with Chemotherapy-Induced Anemia (CIA) Treated with Erythropoiesis-Stimulating Agents (ESAs) in the Pre- Vs Post-National Coverage Determination (NCD) Time Periods.

Elizabeth Apgar, MPH, Tanya M. Burton, PhD, Kay Larholt, ScD, Chris L. Pashos, PhD, Lorie Ellis, PhD, Mekré Senbetta, PharmD, R. Scott McKenzie, MD

Blood (2009) 114 (22): 2482.

https://doi.org/10.1182/blood.V114.22.2482.2482

Published: 2009

Journal Articles

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

David H. Henry, MD, Corey J. Langer, MD, FACP, R. Scott McKenzie, MD, Catherine Tak Piech, MBA, Mekré Senbetta, PharmD, Kathy L. Schulman, MA, Edward J. Stepanski, PhD

Blood (2009) 114 (22): 2491.

https://doi.org/10.1182/blood.V114.22.2491.2491

Published: 2009

Journal Articles

ACE-536, a Novel, GDF-Trap, Promotes Rapid Increase of Red Blood Cells In Vivo in An EPO-Independent Manner.

Dianne Mitchell, Samuel Cadena, Chris Rogers, June Liu, Kathleen Tomkinson, Joe Barberio, Asya Grinberg, Kathryn W. Underwood, R. Scott Pearsall, Ravindra Kumar

Blood (2009) 114 (22): 2505.

https://doi.org/10.1182/blood.V114.22.2505.2505

Published: 2009

Journal Articles

Blood and Resource Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA) in the Pre- and Post-National Coverage Determination (NCD) Timeframes: Results From An Electronic Medical Record Study.

Tanya Burton, PhD, Luke Boulanger, MA, MBA, Kay Larholt, ScD, Chris L. Pashos, PhD, R. Scott McKenzie, MD, Mekré Senbetta, PharmD, Janice Lopez, PharmD, Devi Sundaresan, MS, Peggy Preusse, RN, Christopher Seidler, MD

Blood (2009) 114 (22): 2472.

https://doi.org/10.1182/blood.V114.22.2472.2472

Published: 2009

Journal Articles

ACE-536, a Novel GDF-Trap, Increases Hemoglobin, Hematocrit, and Red Blood Cell Levels in Rats and Monkeys.

Kenneth Loveday, Ph.D, Doriana Froim, Ph.D, Anna Pisania, Ph.D., Alissa Fernald, Mathew Spaits, R. Scott Pearsall, Ph.D., Ravi Kumar, Ph.D., Kathryn W. Underwood, Ph.D.

Blood (2009) 114 (22): 3603.

https://doi.org/10.1182/blood.V114.22.3603.3603

Published: 2009

Journal Articles

Administration of a Novel GDF Trap Prevents Anemia Induced by Renal Insufficiency and Augments Recovery From Blood Loss.

Samuel M. Cadena, Dianne Mitchell, Jeff Ucran, Katia Liharska, Dianne Sako, Travis Monnell, Ravindra Kumar, Kathryn W. Underwood, R. Scott Pearsall, Ph.D.

Blood (2009) 114 (22): 4037.

https://doi.org/10.1182/blood.V114.22.4037.4037

Published: 2009

Journal Articles

Stable gene transfer and expression in cord blood–derived CD34 + hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system

Xingkui Xue, Xin Huang, Sonja E. Nodland, Lajos Mátés, Linan Ma, Zsuzsanna Izsvák, Zoltán Ivics, Tucker W. LeBien, R. Scott McIvor, John E. Wagner, Xianzheng Zhou

Blood (2009) 114 (7): 1319–1330.

https://doi.org/10.1182/blood-2009-03-210005

Published: 2009

Includes: Supplemental data

Journal Articles

Zebrafish runx1 promoter-EGFP transgenics mark discrete sites of definitive blood progenitors

Enid Yi Ni Lam, Jackie Y. M. Chau, Maggie L. Kalev-Zylinska, Timothy M. Fountaine, R. Scott Mead, Christopher J. Hall, Philip S. Crosier, Kathryn E. Crosier, Maria Vega Flores

Blood (2009) 113 (6): 1241–1249.

https://doi.org/10.1182/blood-2008-04-149898

Published: 2009

Includes: Supplemental data

NARROW

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Modified Actriib-Fc Fusion Protein (ACE-536) Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia In a Murine Model Of Myelodysplastic Syndrome and Improves Overall Survival

ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in a Murine Model of Myelodysplastic Syndromes

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in Myelodysplastic Syndromes

Linking air pollution exposure with thrombosis

RAP-536 Accelerates Recovery From Chemotherapy-Induced Anemia (CIA) without Promoting Tumor Growth In Murine Models of Cancer and CIA

ACE-536, a Modified Type II Activin Receptor Increases Red Blood Cells In Vivo by Promoting Maturation of Late Stage Erythroblasts

RAP-536, A Soluble Activin Receptor Type IIb Murine IgG-Fc Fusion Protein, Prevents Myelodysplastic Syndrome Related Anemia

RAP-011, a Soluble Activin Receptor Type IIa Murine IgG-Fc Fusion Protein, Prevents Chemotherapy Induced Anemia.

Hematologic and Hospitalization Outcomes in Patients with Chemotherapy-Induced Anemia (CIA) Treated with Erythropoiesis-Stimulating Agents (ESAs) in the Pre- Vs Post-National Coverage Determination (NCD) Time Periods.

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

ACE-536, a Novel, GDF-Trap, Promotes Rapid Increase of Red Blood Cells In Vivo in An EPO-Independent Manner.

Blood and Resource Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA) in the Pre- and Post-National Coverage Determination (NCD) Timeframes: Results From An Electronic Medical Record Study.

ACE-536, a Novel GDF-Trap, Increases Hemoglobin, Hematocrit, and Red Blood Cell Levels in Rats and Monkeys.

Administration of a Novel GDF Trap Prevents Anemia Induced by Renal Insufficiency and Augments Recovery From Blood Loss.

Stable gene transfer and expression in cord blood–derived CD34 + hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system

Zebrafish runx1 promoter-EGFP transgenics mark discrete sites of definitive blood progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only